Recent changes

Jump to navigation Jump to search

Track the most recent changes to the wiki on this page.

Recent changes options Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide registered users | Hide anonymous users | Hide my edits | Show bots | Hide minor edits
Show new changes starting from 17:29, 19 April 2024
   
 
List of abbreviations:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes

19 April 2024

N    16:30  Sparsentan diffhist +8,644 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
     16:24  (Upload log) [Kosar Doraghi‎ (4×)]
     
16:24 Kosar Doraghi talk contribs uploaded File:IMG 1046.jpeg
     
16:14 Kosar Doraghi talk contribs uploaded File:IMG 1045.jpeg
     
16:11 Kosar Doraghi talk contribs uploaded File:IMG 1047.jpeg
     
16:05 Kosar Doraghi talk contribs uploaded File:IMG 1044.jpeg
     16:17  Somatic symptom disorder diffhist +485 Badgettrg talk contribs (→‎Treatment)
 m   07:50  Non-degenerate nucleotides per response element‎‎ 2 changes history +943 [Marshallsumter‎ (2×)]
 m   
07:50 (cur | prev) +779 Marshallsumter talk contribs (→‎Tabulation of counts)
 m   
01:58 (cur | prev) +164 Marshallsumter talk contribs (→‎Tabulation of counts)

18 April 2024

 m   22:49  Non-degenerate nucleotides per response element‎‎ 4 changes history +2,760 [Marshallsumter‎ (4×)]
 m   
22:49 (cur | prev) +564 Marshallsumter talk contribs (→‎Tabulation of counts)
 m   
20:37 (cur | prev) +1,206 Marshallsumter talk contribs (→‎Tabulation of counts)
 m   
08:39 (cur | prev) +727 Marshallsumter talk contribs (→‎Tabulation of counts)
 m   
04:35 (cur | prev) +263 Marshallsumter talk contribs (→‎Tabulation of counts)
 m   18:29  Xenobiotic response element gene transcriptions‎‎ 2 changes history +93 [Marshallsumter‎ (2×)]
 m   
18:29 (cur | prev) +29 Marshallsumter talk contribs (→‎QRDRE analysis and results)
 m   
18:27 (cur | prev) +64 Marshallsumter talk contribs (→‎QRDRE analysis and results)
     12:48  User:Edzelco diffhist +96 Edzelco talk contribs (→‎Pages Authored/Co-authored/Collaborated)
     12:45  Momelotinib‎‎ 2 changes history +34,070 [Edzelco‎ (2×)]
     
12:45 (cur | prev) −220 Edzelco talk contribs
     
12:44 (cur | prev) +34,290 Edzelco talk contribs
     12:12  Motixafortide diffhist +26,053 Edzelco talk contribs
     11:49  Pozelimab-bbfg diffhist +2,390 Edzelco talk contribs
     11:42  Palovarotene diffhist +39,181 Edzelco talk contribs
     11:16  Elranatamab-bcmm diffhist +32,847 Edzelco talk contribs
     06:18  Endocarditis overview diffhist +2,588 Kosar Doraghi talk contribs

17 April 2024

N    20:47  SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY‎‎ 3 changes history +364 [Hafiza Amna Qadeer‎ (3×)]
     
20:47 (cur | prev) −13 Hafiza Amna Qadeer talk contribs (minor edit) Tag: Visual edit
     
20:46 (cur | prev) +377 Hafiza Amna Qadeer talk contribs (new page minor edit) Tag: Visual edit
N    
19:33 (cur | prev) 0 Hafiza Amna Qadeer talk contribs (Created blank page)
 m   18:11  Non-degenerate nucleotides per response element diffhist +438 Marshallsumter talk contribs (→‎Tabulation of counts)
N    08:08  Elranatamab-bcmm diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:08  Palovarotene diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:08  Pozelimab-bbfg diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:07  Motixafortide diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:07  Momelotinib diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:06  Cipaglucosidase alfa-atga diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:05  Etrasimod diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:05  Zilucoplan diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:04  Bimekizumab diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:04  Vamorolone diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:04  Mirikizumab-mrkz diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
N    08:03  Toripalimab-tpzi diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
     08:02  User:Edzelco‎‎ 5 changes history +99 [Edzelco‎ (5×)]
     
08:02 (cur | prev) +18 Edzelco talk contribs (→‎Pages Authored/Co-authored/Collaborated)
     
07:53 (cur | prev) +26 Edzelco talk contribs (→‎Pages Authored/Co-authored/Collaborated)
     
07:44 (cur | prev) 0 Edzelco talk contribs (→‎Pages Authored/Co-authored/Collaborated)
     
07:44 (cur | prev) +36 Edzelco talk contribs (→‎Pages Authored/Co-authored/Collaborated)
     
07:43 (cur | prev) +19 Edzelco talk contribs (→‎Pages Authored/Co-authored/Collaborated)
N    08:02  Fruquintinib diffhist +25,648 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
N    07:53  Taurolidine, heparin‎‎ 2 changes history +9,993 [Edzelco‎ (2×)]
     
07:53 (cur | prev) 0 Edzelco talk contribs
N    
07:52 (cur | prev) +9,993 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
N    07:43  Repotrectinib diffhist +32,783 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
N    07:34  Efbemalenograstim alfa-vuxw‎‎ 3 changes history +20,126 [Edzelco‎ (3×)]
     
07:34 (cur | prev) 0 Edzelco talk contribs
     
07:33 (cur | prev) +51 Edzelco talk contribs
N    
07:32 (cur | prev) +20,075 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")